Alphamab Oncology licenses JSKN016 ex-China rights to Pathos AI for up to USD 2.09 billion

PUBT · 2d ago
Alphamab Oncology licenses JSKN016 ex-China rights to Pathos AI for up to USD 2.09 billion
  • Alphamab Oncology licensed JSKN016 to Pathos AI on Aug. 3, 2026 for development, manufacturing, commercialization outside Greater China.
  • Deal includes a non-refundable upfront payment of USD 125 million; total potential consideration up to USD 2.09 billion tied to milestones.
  • Alphamab also secured tiered royalties from high-single digit to low-double digit rates on annual net sales in the licensed territory.
  • Pathos AI granted a warrant allowing Alphamab to subscribe for Pathos AI preferred stock with an aggregate subscription price of USD 62.5 million.
  • Alphamab retained full rights to develop, manufacture, commercialize JSKN016 in the Chinese Mainland, Hong Kong, Macau, Taiwan.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alphamab Oncology published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260804-12269881), on August 04, 2026, and is solely responsible for the information contained therein.